封面
市場調查報告書
商品編碼
1212648

急性心臟衰竭(AHF)治療的全球市場

Acute Heart Failure (AHF) Therapeutics

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 299 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

急性心臟衰竭(AHF)治療的全球市場2030年前將達到29億美元

在COVID-19後改變的商務環境中,2022年5億9,970萬美元的急性心臟衰竭(AHF)治療的全球市場2030年前將達到29億美元的修正規模,在2022年~2030年分析期間預計將以21.7%的年複合成長率增長。本報告所分析之市場區隔之一的強心配糖體將記錄年複合成長率22.3%,到分析期間結束時將達到7億6,240萬美元。考慮疫情後的復甦,B 受體阻滯劑領域今後8年的年複合成長率將修正為25.1%。

美國市場估算為1億6,340萬美元,中國則將以年複合成長率30.4%增長

美國的急性心臟衰竭(AHF)治療市場在2022年估算為1億6,340萬美元。作為世界第2大經濟大國的中國,在2022年~2030年複合成長率預計將為30.4%,2030年達到8億4,120萬美元的市場規模。其他熱門的地區市場有日本和加拿大,在2022年~2030年預計將各以16.3%和18.4%的速度成長。在歐洲市場中,德國預計將以年複合成長率約17.1%成長。澳洲,印度,韓國等國家的推動下亞太地區的市場2030年前將達到4億3,340萬美元。

調查對像企業範例

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardiorentis AG
  • CVie Therapeutics Limited
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • PhaseBio Pharmaceuticals, Inc.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP-6845

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Acute Heart Failure (AHF) Therapeutics Market to Reach $2.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Acute Heart Failure (AHF) Therapeutics estimated at US$599.7 Million in the year 2022, is projected to reach a revised size of US$2.9 Billion by 2030, growing at a CAGR of 21.7% over the analysis period 2022-2030. Cardiac Glycosides, one of the segments analyzed in the report, is projected to record a 22.3% CAGR and reach US$762.4 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the B-Blockers segment is readjusted to a revised 25.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $163.4 Million, While China is Forecast to Grow at 30.4% CAGR

The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$163.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$841.2 Million by the year 2030 trailing a CAGR of 30.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.3% and 18.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 17.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433.4 Million by the year 2030.

Select Competitors (Total 93 Featured):

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardiorentis AG
  • CVie Therapeutics Limited
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • PhaseBio Pharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Market Outlook
    • Recent Market Activity
    • Sizing the AHF Market
    • Acute Heart Failure - An Overview of the Disease and Available Therapeutics
    • Diuretics and Vasodilators - The First Line Therapy for AHF
    • Other Known Drugs for AHF - Lower Efficacy Thwarts Use
    • Acute Heart Failure (AHF) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Bayer AG (Germany)
    • Bristol-Myers Squibb Company (USA)
    • Cardiorentis AG (Switzerland)
    • CVie Therapeutics Limited (Taiwan)
    • Cytokinetics, Inc. (USA)
    • Merck & Co. (USA)
    • Novartis AG (Switzerland)
    • Orion Corporation (Finland)
    • PhaseBio Pharmaceuticals, Inc. (USA)
  • 3. MARKET TRENDS & DRIVERS
    • Conventional Therapies Leave Considerable Unmet Needs
    • Novel Treatments Offer a Ray of Hope
    • Key AHF Therapeutics in the Pipeline
    • Serelaxin Nears Trial Readout form RELAX-AHF-2
    • Ularitide - A Novel Drug in Development for AHF
    • The Litany of Drug Failures Expands, Emphasis on Prevention Grows
    • Other Promising Drugs under Development
    • Research Findings
    • Kidney Dysfunction - Predictor of Acute Heart failure
    • Genetic Influence on Heart Disease among African Americans
    • Higher Body Mass Index - A Key Risk Factor for AHF
    • Supplemental Oxygen Therapy May not be for All Cases of AHF
    • Macro Growth Drivers
    • Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics
    • Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Cardiac Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Cardiac Glycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for B-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for B-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 12: World 8-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World 8-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 16: World 8-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 18: World 8-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 20: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 21: World Acute Heart Failure (AHF) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 23: USA 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: USA 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Canada 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • JAPAN
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Japan 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Japan 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • CHINA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 34: China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 35: China 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 36: China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 37: China 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • EUROPE
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 39: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 41: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 42: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 43: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • FRANCE
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: France 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 46: France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 47: France 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • GERMANY
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Germany 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 50: Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Germany 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • ITALY
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 53: Italy 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 54: Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 55: Italy 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • UNITED KINGDOM
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 56: UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: UK 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 58: UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 59: UK 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • SPAIN
    • TABLE 60: Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 61: Spain 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 62: Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Spain 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • RUSSIA
    • TABLE 64: Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Russia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 66: Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Russia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 68: Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Rest of Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 70: Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 71: Rest of Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 73: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2023 & 2030
    • TABLE 74: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 76: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 77: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • AUSTRALIA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 78: Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 79: Australia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 80: Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Australia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • INDIA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 82: India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 83: India 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 84: India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 85: India 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • SOUTH KOREA
    • TABLE 86: South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: South Korea 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 88: South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 89: South Korea 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 90: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 91: Rest of Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 92: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • LATIN AMERICA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 94: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 95: Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2023 & 2030
    • TABLE 96: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 97: Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 98: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • ARGENTINA
    • TABLE 100: Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 101: Argentina 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 102: Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 103: Argentina 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • BRAZIL
    • TABLE 104: Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Brazil 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 106: Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 107: Brazil 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • MEXICO
    • TABLE 108: Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 109: Mexico 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 110: Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Mexico 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 112: Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 113: Rest of Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 114: Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 115: Rest of Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • MIDDLE EAST
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 116: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 117: Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2023 & 2030
    • TABLE 118: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 119: Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 120: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 121: Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • IRAN
    • TABLE 122: Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Iran 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 124: Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 125: Iran 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • ISRAEL
    • TABLE 126: Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 127: Israel 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 128: Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Israel 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • SAUDI ARABIA
    • TABLE 130: Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 131: Saudi Arabia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 132: Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 133: Saudi Arabia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 134: UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: UAE 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 136: UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 137: UAE 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 138: Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 139: Rest of Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 140: Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Rest of Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
  • AFRICA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 142: Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 143: Africa 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
    • TABLE 144: Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 145: Africa 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030

IV. COMPETITION